These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 30058714)
1. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Lorentino F; Labopin M; Bernardi M; Ciceri F; Socié G; Cornelissen JJ; Esteve J; Ruggeri A; Volin L; Yacoub-Agha I; Craddock C; Passweg J; Blaise D; Gedde-Dahl T; Poiani M; Fegueux N; Mohty M; Nagler A; Am J Hematol; 2018 Oct; 93(10):1236-1244. PubMed ID: 30058714 [TBL] [Abstract][Full Text] [Related]
2. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis. Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644 [TBL] [Abstract][Full Text] [Related]
3. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. Piemontese S; Ciceri F; Labopin M; Arcese W; Kyrcz-Krzemien S; Santarone S; Huang H; Beelen D; Gorin NC; Craddock C; Gulbas Z; Bacigalupo A; Mohty M; Nagler A; J Hematol Oncol; 2017 Jan; 10(1):24. PubMed ID: 28103944 [TBL] [Abstract][Full Text] [Related]
4. Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. Saraceni F; Labopin M; Gorin NC; Blaise D; Tabrizi R; Volin L; Cornelissen J; Cahn JY; Chevallier P; Craddock C; Wu D; Huynh A; Arcese W; Mohty M; Nagler A; J Hematol Oncol; 2016 Sep; 9(1):79. PubMed ID: 27589849 [TBL] [Abstract][Full Text] [Related]
5. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089 [TBL] [Abstract][Full Text] [Related]
6. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146 [TBL] [Abstract][Full Text] [Related]
7. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553 [TBL] [Abstract][Full Text] [Related]
8. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission. Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758 [TBL] [Abstract][Full Text] [Related]
10. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196 [TBL] [Abstract][Full Text] [Related]
11. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Nagler A; Labopin M; Mielke S; Passweg J; Blaise D; Gedde-Dahl T; Cornelissen JJ; Salmenniemi U; Yakoub-Agha I; Reményi P; Socié G; van Gorkom G; Labussière-Wallet H; Huang XJ; Rubio MT; Byrne J; Craddock C; Griškevičius L; Ciceri F; Mohty M Bone Marrow Transplant; 2023 Jul; 58(7):791-800. PubMed ID: 37045942 [TBL] [Abstract][Full Text] [Related]
12. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438 [TBL] [Abstract][Full Text] [Related]
14. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Nagler A; Labopin M; Dholaria B; Angelucci E; Afanasyev B; Cornelissen JJ; Sica S; Meijer E; Ciceri F; Van Gorkom G; Kröger N; Martin H; Pioltelli P; Risitano A; Canaani J; Savani BN; Sanz J; Mohty M Clin Cancer Res; 2021 Feb; 27(3):843-851. PubMed ID: 33148668 [TBL] [Abstract][Full Text] [Related]
17. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518 [TBL] [Abstract][Full Text] [Related]
18. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Battipaglia G; Boumendil A; Labopin M; Ciceri F; Tischer J; Stelljes M; Ehninger G; Beelen D; Finke J; Van Lint MT; Eder M; Afanasyev B; Fanin R; Mohty M; Ruggeri A; Nagler A Bone Marrow Transplant; 2019 Sep; 54(9):1499-1510. PubMed ID: 30718798 [TBL] [Abstract][Full Text] [Related]
19. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512 [TBL] [Abstract][Full Text] [Related]
20. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]